Strong Buy Rated Stocks
SLNO is part of our Strong Buy Rated Stocks screen, indicating it has a strong buy ratings from analysts and supporting business quality.
SOLENO THERAPEUTICS INC (SLNO) Stock Price & Overview
NASDAQ:SLNO • US8342033094
Current stock price
52.87 USD
+0.05 (+0.09%)
At close:
52.87 USD
0 (0%)
After Hours:
The current stock price of SLNO is 52.87 USD. Today SLNO is up by 0.09%. In the past month the price increased by 33.88%. In the past year, price decreased by -29.72%.
SLNO Key Statistics
52-Week Range29.43 - 90.3199
Current SLNO stock price positioned within its 52-week range.
1-Month Range52.15 - 52.88
Current SLNO stock price positioned within its 1-month range.
- Market Cap
- 2.734B
- P/E
- 229.87
- Fwd P/E
- 13.32
- EPS (TTM)
- 0.23
- Dividend Yield
- N/A
SLNO Stock Performance
Today
+0.09%
1 Week
+0.28%
1 Month
+33.88%
3 Months
+37.11%
Longer-term
6 Months -21.28%
1 Year -29.72%
2 Years +25.64%
3 Years +903.23%
5 Years +242.20%
10 Years N/A
SLNO Stock Chart
SLNO Stock Screens
SLNO currently appears in the following ChartMill screener lists.
RSI Overbought Stocks
SLNO is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
Breakout Setups
SLNO appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
SLNO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SLNO. When comparing the yearly performance of all stocks, SLNO turns out to be only a medium performer in the overall market: it outperformed 46.67% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
SLNO Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to SLNO. SLNO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SLNO Earnings
On February 25, 2026 SLNO reported an EPS of 0.8 and a revenue of 91.73M. The company beat EPS expectations (10.35% surprise) and beat revenue expectations (1.56% surprise).
Next Earnings DateMay 12, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported$0.80
Revenue Reported91.73M
EPS Surprise 10.35%
Revenue Surprise 1.56%
SLNO Forecast & Estimates
19 analysts have analysed SLNO and the average price target is 57.53 USD. This implies a price increase of 8.81% is expected in the next year compared to the current price of 52.87.
For the next year, analysts expect an EPS growth of 1625.13% and a revenue growth 149.64% for SLNO
Analysts
Analysts86.32
Price Target57.53 (8.81%)
EPS Next Y1625.13%
Revenue Next Year149.64%
SLNO Index Membership
SLNO is currently included in the following stock indexes tracked on ChartMill.
SLNO Financial Highlights
Over the last trailing twelve months SLNO reported a non-GAAP Earnings per Share(EPS) of 0.23. The EPS increased by 105.4% compared to the year before.
Income Statements
Revenue(TTM)190.41M
Net Income(TTM)20.48M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.75% | ||
| ROA | 3.63% | ||
| ROE | 4.55% | ||
| Debt/Equity | 0.11 |
Chartmill High Growth Momentum
EPS Q2Q%162.99%
Sales Q2Q%N/A
EPS 1Y (TTM)105.4%
Revenue 1Y (TTM)N/A
SLNO Ownership
Ownership
Inst Owners129.57%
Shares51.72M
Float50.80M
Ins Owners1.54%
Short Float %11.42%
Short Ratio1.52
SLNO Industry Overview
SLNO operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
SLNO Latest News, Press Relases and Analysis
7 days ago - By: Chartmill
SLNO Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SLNO
Company Profile
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 182 full-time employees. The company went IPO on 2014-10-23. The firm is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The firm has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Company Info
IPO: 2014-10-23
SOLENO THERAPEUTICS INC
100 Marine Parkway, Suite 400
Redwood City CALIFORNIA 94065 US
CEO: Anish Bhatnagar
Employees: 182
Phone: 13026587581
SOLENO THERAPEUTICS INC / SLNO FAQ
What does SOLENO THERAPEUTICS INC do?
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 182 full-time employees. The company went IPO on 2014-10-23. The firm is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The firm has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
What is the stock price of SOLENO THERAPEUTICS INC today?
The current stock price of SLNO is 52.87 USD. The price increased by 0.09% in the last trading session.
What is the dividend status of SOLENO THERAPEUTICS INC?
SLNO does not pay a dividend.
How is the ChartMill rating for SOLENO THERAPEUTICS INC?
SLNO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the valuation of SOLENO THERAPEUTICS INC (SLNO) based on its PE ratio?
The PE ratio for SOLENO THERAPEUTICS INC (SLNO) is 229.87. This is based on the reported non-GAAP earnings per share of 0.23 and the current share price of 52.87 USD.
Can you provide the market cap for SOLENO THERAPEUTICS INC?
SOLENO THERAPEUTICS INC (SLNO) has a market capitalization of 2.73B USD. This makes SLNO a Mid Cap stock.
What is the ownership structure of SOLENO THERAPEUTICS INC (SLNO)?
You can find the ownership structure of SOLENO THERAPEUTICS INC (SLNO) on the Ownership tab.